Andrea Raballo Selected Research

Psychotic Disorders (Schizoaffective Disorder)

3/2024	Baseline Antipsychotic Dose and Transition to Psychosis in Individuals at Clinical High Risk: A Systematic Review and Meta-Analysis.
8/2023	Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis.
5/2023	Baseline antipsychotic prescription and short-term outcome indicators in individuals at clinical high-risk for psychosis: Findings from the Parma At-Risk Mental States (PARMS) program.
1/2023	The temporal dynamics of transition to psychosis in individuals at clinical high-risk (CHR-P) shows negative prognostic effects of baseline antipsychotic exposure: a meta-analysis.
1/2023	Obsessive-compulsive symptoms in the schizophrenia-spectrum: current developments in psychopathology research.
1/2023	Do antidepressants prevent transition to psychosis in individuals at clinical high-risk (CHR-P)? Systematic review and meta-analysis.
1/2023	Anhedonia and suicidal ideation in young people with early psychosis: Further findings from the 2-year follow-up of the ReARMS program.
5/2022	Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision.
2/2022	Subjective experience of aberrant salience in young people at Ultra-High Risk (UHR) for psychosis: a cross-sectional study.
1/2022	Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrea Raballo Research Topics

Disease

39	Psychotic Disorders (Schizoaffective Disorder) 03/2024 - 01/2011
10	Schizophrenia (Dementia Praecox) 01/2023 - 01/2015
4	Anhedonia 01/2023 - 04/2020
4	Mental Disorders (Mental Disorder) 01/2021 - 01/2018
1	Aphasia (Dysphasia) 12/2021
1	Mood Disorders (Mood Disorder) 01/2021
1	Major Depressive Disorder (Major Depressive Disorders) 01/2020
1	Substance-Related Disorders (Drug Abuse) 11/2019
1	Hallucinations (Hallucination) 04/2012

Drug/Important Bio-Agent (IBA)

21	Polytetrafluoroethylene (Teflon)FDA Link 01/2023 - 01/2011
16	Antipsychotic Agents (Antipsychotics)IBA 03/2024 - 08/2016
3	Antidepressive Agents (Antidepressants)IBA 08/2023 - 01/2020
3	Silver Sulfadiazine (SSD)FDA LinkGeneric 01/2023 - 01/2021
3	2-bromolysergic acid diethylamide (BOL)IBA 01/2021 - 04/2020
2	SolutionsIBA 12/2021 - 04/2012
1	BenzodiazepinesIBA 08/2023
1	Appetite Depressants (Anorectics)IBA 06/2022
1	mesoglycanIBA 01/2022
1	PlasticsIBA 11/2020
1	ceramide heptassaccharide (CHSC)IBA 11/2018
1	Genetic Markers (Genetic Marker)IBA 01/2018

Therapy/Procedure

1	CARE protocol 12/2021
1	Disarticulation 01/2016
1	Self-Testing 01/2015